Key Highlights
- 2.35 is the loss per share, shown as -2.35, that the consensus estimate implies for Inhibrx Biosciences, Inc. (NASDAQ:INBX) in its third quarter 2026 report after the market closes on November 13, 2026.
- 36.7 million is the USD net loss for the second quarter of 2026, or USD 2.34 per share, compared with a USD 28.7 million loss and USD 1.85 per share a year earlier.
- 219.5 million is the USD cash balance as of August 6, 2026, up from USD 133.3 million at June 30 after a USD 100.0 million Loan draw on July 15, 2026.
- 1.33 billion is the USD market Capitalization per the screener snapshot, while the FDA set a PDUFA goal date of April 14, 2027 for ozekibart in conventional chondrosarcoma.
What Investors Expect From Inhibrx Biosciences, Inc. (NASDAQ:INBX) on November 13, 2026
Inhibrx Biosciences, Inc. is listed to report third quarter 2026 results on November 13, 2026, after the market closes (AMC). The consensus estimate is a loss of 2.35 per share, per the screener snapshot, with a market capitalization of USD 1.33 billion. That compares with the second quarter loss of USD 2.34 per share on about 15.7 million weighted shares. The company reported no Revenue in the second quarter against USD 1.3 million a year earlier.
The Rationale: Last Reported Quarter and Management Outlook for Inhibrx Biosciences, Inc. (NASDAQ:INBX)
Second quarter Research and Development expense was USD 23.9 million versus USD 22.3 million, general and administrative expense was USD 8.3 million versus USD 6.4 million, and other expense was USD 4.5 million. Six-month net loss was USD 70.1 million, or USD 4.49 per share. The BLA for ozekibart was accepted in June 2026. Management planned progression-free survival data for INBRX-106 in the third quarter of 2026, an FDA meeting in the fourth quarter on colorectal cancer, and interim colorectal data in the first quarter of 2027.
Valuation, Liquidity and Risks for Inhibrx Biosciences, Inc. (NASDAQ:INBX)
Per the screener snapshot, the Market Value is USD 1.33 billion. Long-term debt, net was USD 176.3 million against a USD 175.0 million loan balance, and stockholders' Deficit was USD 53.0 million at June 30, 2026. Up to USD 225.0 million of additional loan funding may be available at the lender's discretion. No explicit cash runway estimate was given. Risks include clinical and regulatory outcomes, Debt service, continued losses and dependence on a small number of programs. The INBRX-106 trial result was not found in published coverage.
Where Things Stand
Where things stand: Inhibrx Biosciences, Inc. (NASDAQ:INBX) reports after the market closes on November 13, 2026 with a consensus estimate of -2.35 per share and a market value of USD 1.33 billion per the screener snapshot. Cash of USD 219.5 million as of August 6, 2026 follows a USD 100.0 million loan draw, while the second quarter net loss was USD 36.7 million. Ozekibart faces an April 14, 2027 FDA goal date, a fourth quarter FDA meeting on colorectal cancer and interim colorectal data expected in the first quarter of 2027. Investors will watch spending, debt and trial updates. This article is informational and is not Investment advice.
_11_19_2026_19_19_13_574021.jpg)





Please wait processing your request...